Vyome Holdings Reports Second-Quarter 2026 Results and Highlights Progress Across Clinical Pipeline Vyome Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for immuno-inflammatory and rare diseases, has announced its financial results for the second quarter ended June 30,…
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer to Advance Clinical Development Pipeline AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics through its proprietary boron chemistry platform, has announced the appointment of…
Charles River Laboratories and Medigen Vaccine Biologics Collaborate to Advance Next-Generation Multivalent Enterovirus Vaccine Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) have entered into a strategic collaboration focused on the characterization and validation of the virus seed bank…
Tolerance Bio Licenses Efineptakin Alfa From NeoImmuneTech to Advance Thymus-Targeted Therapies Tolerance Bio, Inc., a biotechnology company focused on preserving, regenerating, and modulating thymic function to address immune-related diseases and potentially extend healthspan, has entered into an exclusive license agreement…
VectorBuilder and Lir Therapeutics Partner to Develop Scalable, AI-Engineered AAV Capsids for Gene Therapy VectorBuilder, a global provider of gene delivery technologies, and Lir Therapeutics, a biotechnology company focused on applying artificial intelligence to viral vector engineering, have announced a…
Canopy Growth Distributes 2026 Annual Meeting Materials and Urges Shareholders to Vote Ahead of September 25 Meeting Canopy Growth Corporation, a global company focused on the cannabis sector, has announced that it has mailed, or mailed notices regarding the availability…
AIVITA Biomedical Named 2026 Prix Galien USA “Best Startup” Nominee for Personalized Immunotherapy Innovation AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines and immunotherapies for infectious diseases and cancer, has been named a 2026 Prix Galien USA nominee in…
Amprion and MLM Medical Labs Expand Access to α-Synuclein Testing for Neurodegenerative Disease Trials Across Europe Amprion, a global leader in advancing the diagnosis and characterization of neurodegenerative disorders through seed amplification testing, has announced a strategic licensing collaboration with…
AbCellera Reports Positive Phase 2 Results for ABCL635, Advancing Long-Acting Non-Hormonal Treatment for Menopausal Hot Flashes AbCellera has announced encouraging top-line results from the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating ABCL635, an investigational antibody designed…
Multicenter Study Demonstrates Superior Outcomes with equicenta® CTM for Returning Performance Horses to Work Equine Performance Labs (EPL), the company behind equicenta® CTM, has announced the publication of new peer-reviewed clinical research demonstrating the potential of its regenerative therapy to…
Helen Branswell Named Recipient of the 2026 Kovler Prize for Trust in Life Science Journalism The Foundation for the National Institutes of Health (FNIH) has announced that renowned infectious disease journalist Helen Branswell, an award-winning correspondent with STAT, has been…
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Neuroplastogenic Candidate EB-003 Enveric Biosciences, a clinical-stage biotechnology company focused on developing next-generation neuroplastogenic small-molecule therapies for psychiatric and neurological disorders, has announced new preclinical findings that further…